Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | STS | P08842 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9765605 | 0.94 | ALDH1A1 (0.33) | DPP4LMNASTSBACE1CYP2C19 | |
| SCHEMBL3817812 | 0.85 | ALDH1A1 (0.37) | DPP4STSBACE1 | |
| SCHEMBL9843658 | 0.82 | ALDH1A1 (0.38) | DPP4LMNABACE1 | |
| SCHEMBL26939298 | 0.78 | CYP2C19 (0.32) | LMNACYP2C19 | |
| SCHEMBL26939295 | 0.76 | — | — | |
| SCHEMBL26939293 | 0.75 | MEN1 (0.32) | CYP2C19 | |
| SCHEMBL28679791 | 0.75 | ALDH1A1 (0.34) | LMNABACE1 | |
| SCHEMBL7276909 | 0.72 | ALDH1A1 (0.40) | DPP4BACE1KDM4E | |
| SCHEMBL17294422 | 0.72 | OPRM1 (0.32) | LMNASTS | |
| SCHEMBL2861221 | 0.72 | ALDH1A1 (0.38) | DPP4BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632953-B2 | Process for the preparation of gabalactam | HIKAL LIMITED (IN) | 2009-12-15 | — | — | US | disclosed |
| EP-1599446-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF GABALACTAM | HIKAL LTD (IN) | 2009-08-12 | — | — | EP | disclosed |
| US-20060135789-A1 | Process for the preparation of gabalactam | HIKAL LIMITED | 2006-06-22 | — | — | US | disclosed |
| EP-1599446-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF GABALACTAM | Hikal Ltd. (IN) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004046108-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF GABALACTAM | HIKAL LTD. (IN) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135789-A1 | Process for the preparation of gabalactam | GABRA5, GABRB1, GABRA6 | DPP4 144/4885LMNA 4251/4885STS 1106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.